On Monday, Fate Therapeutics Inc (NASDAQ: FATE) opened higher 10.09% from the last session, before settling in for the closing price of $1.09. Price fluctuations for FATE have ranged from $0.66 to $4.20 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -2.63%. Company’s average yearly earnings per share was noted 25.31% at the time writing. With a float of $109.47 million, this company’s outstanding shares have now reached $114.66 million.
Let’s determine the extent of company efficiency that accounts for 181 employees. In terms of profitability, gross margin is 61.3%, operating margin of -2271.23%, and the pretax margin is -2025.05%.
Fate Therapeutics Inc (FATE) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Fate Therapeutics Inc is 5.08%, while institutional ownership is 70.49%. The most recent insider transaction that took place on Aug 04 ’25, was worth 9,573. In this transaction an insider of this company sold 9,037 shares at a rate of $1.06, taking the stock ownership to the 397,670 shares. Before that another transaction happened on Aug 04 ’25, when Company’s President and CEO sold 14,466 for $1.06, making the entire transaction worth $15,396. This insider now owns 334,898 shares in total.
Fate Therapeutics Inc (FATE) Earnings and Forecasts
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.4 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.41) by 0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.25 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 25.31% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 14.32% during the next five years compared to -2.63% drop over the previous five years of trading.
Fate Therapeutics Inc (NASDAQ: FATE) Trading Performance Indicators
Check out the current performance indicators for Fate Therapeutics Inc (FATE). In the past quarter, the stock posted a quick ratio of 8.04. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 16.34.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.45, a number that is poised to hit -0.31 in the next quarter and is forecasted to reach -1.16 in one year’s time.
Technical Analysis of Fate Therapeutics Inc (FATE)
Looking closely at Fate Therapeutics Inc (NASDAQ: FATE), its last 5-days average volume was 2.27 million, which is a jump from its year-to-date volume of 2.05 million. As of the previous 9 days, the stock’s Stochastic %D was 63.64%.
During the past 100 days, Fate Therapeutics Inc’s (FATE) raw stochastic average was set at 46.50%, which indicates a significant decrease from 87.88% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0897 in the past 14 days, which was lower than the 0.1149 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.1728, while its 200-day Moving Average is $1.4168. However, in the short run, Fate Therapeutics Inc’s stock first resistance to watch stands at $1.2533. Second resistance stands at $1.3067. The third major resistance level sits at $1.3933. If the price goes on to break the first support level at $1.1133, it is likely to go to the next support level at $1.0267. Should the price break the second support level, the third support level stands at $0.9733.
Fate Therapeutics Inc (NASDAQ: FATE) Key Stats
There are currently 115,330K shares outstanding in the company with a market cap of 138.40 million. Presently, the company’s annual sales total 13,630 K according to its annual income of -186,260 K. Last quarter, the company’s sales amounted to 1,630 K and its income totaled -37,620 K.
